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Abstract
Background Traditional adverse event (AE) reporting
systems have been slow in adapting to online AE reporting
from patients, relying instead on gatekeepers, such as cli-
nicians and drug safety groups, to verify each potential
event. In the meantime, increasing numbers of patients
have turned to social media to share their experiences with
drugs, medical devices, and vaccines.
Objective The aim of the study was to evaluate the level
of concordance between Twitter posts mentioning AE-like
reactions and spontaneous reports received by a regulatory
agency.
Methods We collected public English-language Twitter
posts mentioning 23 medical products from 1 November
2012 through 31 May 2013. Data were ﬁltered using a
semi-automated process to identify posts with resemblance
to AEs (Proto-AEs). A dictionary was developed to trans-
late Internet vernacular to a standardized regulatory
ontology for analysis (MedDRA
 ). Aggregated frequency
of identiﬁed product-event pairs was then compared with
data from the public FDA Adverse Event Reporting System
(FAERS) by System Organ Class (SOC).
Results Of the 6.9 million Twitter posts collected, 4,401
Proto-AEs were identiﬁed out of 60,000 examined.
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Key Points
Existing post-marketing adverse event surveillance
systems suffer from under-reporting and data
processing lags.
Social media services such as Twitter are seeing
increasing adoption, and patients are using them to
describe adverse experiences with medical products.
An analysis of 4,401 of these ‘posts with
resemblance to adverse events’ (‘Proto-AEs’) from
Twitter found concordance with consumer-reported
FDA Adverse Event Reporting System reports at the
System Organ Class level.
Drug Saf (2014) 37:343–350
DOI 10.1007/s40264-014-0155-xAutomated, dictionary-based symptom classiﬁcation had
72 % recall and 86 % precision. Similar overall distribu-
tion proﬁles were observed, with Spearman rank correla-
tion rho of 0.75 (p\0.0001) between Proto-AEs reported
in Twitter and FAERS by SOC.
Conclusion Patients reporting AEs on Twitter showed a
range of sophistication when describing their experience.
Despite the public availability of these data, their appro-
priate role in pharmacovigilance has not been established.
Additional work is needed to improve data acquisition and
automation.
1 Introduction
Pharmacovigilance systems rely on spontaneous adverse
event (AE) reports received by regulatory authorities,
mostly after passing through third-party gatekeepers (bio-
pharmaceutical industry, lawyers, clinicians, and pharma-
cists), generating possible bottlenecks where information
may be lost or misinterpreted. In the USA, 80 % of drug
[1], 35 % of vaccine [2], and 98 % of device [3] AE reports
received by the US FDA come from the biopharmaceutical
industry. In the clinical context, while the true extent of
under-reporting is unknown, a recent study of Medicare
enrollees in a hospital found that 86 % of AEs went
unreported [4]. Meanwhile, the government currently
releases the data approximately 1 year after receipt [5].
This systemic friction results in an important reporting and
information gap that has persisted for decades. Social
media data may provide additional insight when combined
with additional information sources in modern pharmaco-
vigilance systems, including those that can provide a
denominator for rate calculations, such as electronic health
records and administrative claims databases.
Regulatory authorities have recognized the importance of
listening to the patient’s voice at some level, requiring the
collection of patient-reported AEs from online sources [6]
and providing guidance on using patient-reported outcomes
[7]. The most explicit direction in this area to date has come
from the Association of the British Pharmaceutical Industry,
which issued voluntary guidelines for how to approach AEs
reported in third-party social media sites [8]. Their recom-
mendation is ‘‘if a company chooses to ‘listen in’ at non-
company-sponsoredsites,itisrecommendedthattherelevant
pages of the site should be monitored for AE/PC (product
complaint) for the period of the listening activity only.’’
Despite these initial efforts, the information gap also
extends in the opposite direction. As medical product safety
concerns emerge, data collected through health institutions
and ofﬁcial reporting structures may not be available for
months or even years, hindering timely pharmacoepidemi-
ological assessment and public awareness. In the meantime,
most consumers are unlikely to be aware that they can and
should report AEs.
At the same time that there is signiﬁcant under-
reporting of AEs through ofﬁcial channels, new Internet
services have given voice to patients who routinely share
information in public forums, including their experiences
with medical products. Approximately 25 % of Facebook
[9] proﬁles and 90 % of Twitter [10] feeds are fully
public, and a broad range of health-focused forums sup-
port public discussions. Previous studies have suggested
the potential of high-quality data generated by online
social networks at low cost [11–13]. Even users’ search
engine query histories have also been used to identify
AEs [14]. Many users also report AEs publicly, often
expecting that someone is paying attention, as evidenced
by hashtags for regulatory agencies (e.g., #FDA), manu-
facturers (#Pﬁzer, #GSK), and speciﬁc products (#accu-
taneprobz, @EssureProblems). (The hashtag [e.g.,
#accutaneprobz] placed in the body of a post is a way to
categorize or tag the post to allow for quick retrieval via
subsequent searching, similar conceptually to an email
folder; the ‘at’ sign [@] placed in front of a Twitter us-
ername constitutes a ‘mention’, directing the message to
the username in question, similar conceptually to an email
address.) However, these data have not yet been used for
routine safety surveillance and careful consideration must
be given to how to process the information.
In order to assess the feasibility and reliability of har-
nessing social media data for AE surveillance, we analyzed
data from the micro-blogging site Twitter. With posts
limited to 140 characters, we expect that micro-blogging
data are the smallest units of text in which events can be
detected at present. We compared posts mentioning AEs
detected in Twitter with public data derived from the US
FDA Adverse Event Reporting System (FAERS).
2 Methods
Our approach was to ﬁrst collect all English-language
Twitter posts mentioning medical products. We applied
manual and semi-automated techniques to identify posts
with resemblance to AEs. Colloquial language was then
mapped to a standard regulatory dictionary. We then
compared the aggregate frequency of identiﬁed product-
event pairs with FAERS at the organ system level. A data
collection schematic is shown in Fig. 1.
2.1 Data Sources
Twitter data were collected from 1 November 2012
through 31 May 2013, and consisted of public posts
acquired through the general-use streaming application
344 C. C. Freifeld et al.programming interface (API). We chose this data source
because it contains a large volume of publicly available
posts about medical products. Data were stored in dat-
abases using Amazon Web Services (AWS) cloud services.
Since the vast majority of the over 400 million daily
Twitter posts have no relevance to AE reporting, we cre-
ated a list of medical product names and used them as
search term inputs to the Twitter API. Though this
approach may remove posts that contain misspellings,
slang terms, and other oblique references, it allowed us to
start from a manageable data corpus. In order to avoid
confusion with regulatory deﬁnitions of an ‘adverse event’
report, the term ‘Proto-AE’ was coined to signify ‘posts
with resemblance to AEs’, designating posts containing
discussion of AEs identiﬁed in social media sources. The
labeled subset was chosen through a combination of review
of the data in sequence as collected from the API for
convenient time periods, as well as by searching the
unlabeled data for speciﬁc product names and symptom
terms.
Public FAERS data were obtained from the FDA web-
site in text format for the time period concurrent with the
collection of Twitter data, the fourth quarter of 2012 and
ﬁrst quarter of 2013.
2.2 Product Selection
In conjunction with the FDA, a priori selected 23 pre-
scription and over-the-counter drug products in diverse
therapeutic areas were selected for quantitative analysis,
representing new and old medicines, as well as widely used
products and more specialized ones: acetaminophen, ada-
limumab, alprazolam, citalopram, duloxetine, gabapentin,
ibuprofen, isotretinoin, lamotrigine, levonorgestrel, met-
formin, methotrexate, naproxen, oxycodone, paroxetine,
prednisone, pregabalin, sertraline, tramadol, varenicline,
venlafaxine, warfarin, and zolpidem. We also selected
vaccines for inﬂuenza, human papillomavirus (HPV),
hepatitis B, and the combined tetanus/diphtheria/pertussis
(Tdap) vaccine. Whenever possible, we identiﬁed brand
and generic names for each product using the DailyMed
site from the National Library of Medicine and the FDA’s
Orange Book.
2.3 Adverse Event (AE) Identiﬁcation in Twitter
The next step was classiﬁcation of the information, which
includes ﬁltering the corpus to remove items irrelevant to
AEs. To determine whether or not a given post constitutes
Fig. 1 Data collection scheme
for both Twitter and FAERS
reports. API application
programming interface, FAERS
FDA Adverse Event Reporting
System, FDA Food and Drug
Administration, MedDRA
Medical Dictionary for
Regulatory Activities, NLP
natural language processing,
Proto-AEs posts with
resemblance to adverse events
Digital Drug Safety Surveillance 345an AE report, we established guidelines for human anno-
tators to consistently identify AE reports. We proceeded
under the general guidance of the four statutorily required
data elements for AE reporting in the USA: an identiﬁable
medical product, an identiﬁable reporter, an identiﬁable
individual, and mention of a negative outcome, though we
did not automatically exclude posts if they failed to meet
one of these criteria. We also considered Twitter accounts
as sufﬁcient to meet the requirement for an identiﬁable
reporter, though this standard is not the current regulatory
expectation for mandatory reporting.
We applied a tree-based dictionary-matching algorithm
to identify both product and symptom mentions. It consists
of three components. First, we loaded the dictionary from a
multi-user editable spreadsheet form into the tree structure
in memory. Two separate product and symptom dictio-
naries were superimposed into a single tree, allowing only
a single pass over the input for both product and symptom
matches. Second, for the extraction step, a tokenizer
stripped punctuation and split the input into a series of
tokens, typically corresponding to words. Finally, we pro-
cessed the tokens one at a time, matching each against the
tree and traversing the tree as matches occurred. If we
reached a leaf in the tree, then a positive match was
established and we returned the identiﬁer for the appro-
priate concept (product or symptom). Because the con-
cordance analysis is based on the output of the algorithm,
its performance characteristics are important. We assessed
the performance of the symptom classiﬁer by manually
examining a random sample of 10 % of the Proto-AEs and
comparing the algorithmically identiﬁed symptoms with
symptoms that a rater (CCF) determined to be attributed to
a product.
We created a curation tool for reviewing and labeling
posts. Two trained raters (CCF, CMM) classiﬁed a con-
venience sample of 61,402 posts. Discrepancies between
raters were adjudicated by three of the authors (CCF,
CMM, ND). Agreement on overlapped subsets increased
from 97.9 to 98.4 % (Cohen’s kappa: 0.97) over successive
rounds of iterative protocol development and classiﬁcation.
The convenience sample was selected as a training dataset
for further development of an automated Bayesian classi-
ﬁer, but the classiﬁer was not used in the analysis presented
in this study. The sample was enriched to include posts that
contained AEs based on preliminary data review.
2.4 Coding of AEs in Twitter
Further natural language processing was required to iden-
tify the event in each post. Starting with the subset of posts
identiﬁed to contain AEs, we developed a dictionary to
convert Internet vernacular to a standardized regulatory
dictionary, namely Medical Dictionary for Regulatory
Activities (MedDRA
 ) version 16 in English. MedDRA
 ,
the Medical Dictionary for Regulatory Activities, termi-
nology is the international medical terminology developed
under the auspices of the International Conference on
Harmonization of Technical Requirements for Registration
of Pharmaceuticals for Human Use (ICH). MedDRA
 
trademark is owned by the International Federation of
Pharmaceutical Manufacturers and Associations (IFPMA)
on behalf of ICH. The ontology matches Internet vernac-
ular to the closest relevant MedDRA preferred term, but
allows for less speciﬁc higher-level terms to be used when
not enough detail is available for matching to a preferred
term. The empirically derived dictionary currently contains
over 4,800 terms spread across 257 symptom categories.
For example, the post ‘‘So much for me going to sleep at
12. I am wide awake thanks prednisone and albuterol’’ (30
Sep 2013), would be coded to the MedDRA preferred term
‘insomnia’, by identifying ‘wide awake’ as the outcome,
and both prednisone and albuterol as the drugs involved.
Multiple vernacular phrases could be mapped to the same
MedDRA preferred term, such as ‘can’t sleep’ and ‘tossing
and turning’ in the previous example. As noted above and
detailed in Freifeld et al. [15], we used a tree-based text-
matching algorithm to match the raw text from the posts to
the vernacular dictionary. Preferred terms were aggregated
up to the System Organ Class (SOC), the broadest hierar-
chical category in MedDRA.
2.5 AE Identiﬁcation in FAERS
AEs were identiﬁed from public FAERS data for the pro-
ducts of interest using exact name matching for brand and
generic names. Un-duplication was conducted using the
FDA case identiﬁcation number, date of event, country of
occurrence, age, and gender. Reports submitted by con-
sumers were identiﬁed using reporter ﬁeld. All roles (pri-
mary suspect, secondary suspect, etc.) were considered;
preliminary analysis suggested that limiting to primary
suspect medicines did not alter results meaningfully (data
not shown).
2.6 Data Analysis
We analyzed vaccines and drugs separately, since vaccine
AE data from the US Vaccine Adverse Event Reporting
System (VAERS) [16] were not available for this analysis.
We compared prescription and over-the-counter drug AEs
identiﬁed in Twitter posts with corresponding FAERS data
for those products, at the SOC level. This approach is
intended to identify gross patterns, and not to assess the
ability to detect rare but serious AEs.
346 C. C. Freifeld et al.We assessed the precision and recall of the symptom
dictionary-matching algorithm by manual classiﬁcation of
a random sample of 437 Twitter posts (10 % of the full
sample). A single post can contain multiple symptom
mentions; a symptom match was considered a true positive
only if the symptom was considered an AE of one of the
mentioned products.
We did not seek to verify each individual report as
truthful, but rather to identify overall associations between
Twitter and ofﬁcial spontaneous report data as a pre-
liminary proof of concept. We calculated correlation using
the Spearman correlation rank statistic (rho) by the 22 SOC
categories, with a statistical alpha of\0.05.
3 Results
The resulting dataset contained a high volume of irrelevant
information, but provided a useful starting point. Over the
period from 1 November 2012 through 31 May 2013, we
collected a total of 6.9 million Twitter posts (‘tweets’). Of
these, we manually categorized 61,401 as Proto-AEs
(4,401) or not (57,000). While the number of Proto-AEs
represented 7.2 % of the 61,402 posts analyzed, we reit-
erate that this was a convenience sample enriched for
Proto-AEs and should not be interpreted as the prevalence
of AE-related reports in social media. There were 1,400
AEs reported to FAERS from 1 October 2012 through 31
March 2013 for the 23 active ingredients analyzed.
The number of Proto-AEs for each drug were as fol-
lows: acetaminophen (303), adalimumab (21), alprazolam
(332), citalopram (16), duloxetine (49), gabapentin (32),
ibuprofen (1,268), isotretinoin (75), lamotrigine (21),
levonorgestrel (57), metformin (22), methotrexate (18),
naproxen (85), oxycodone (102), paroxetine (19), predni-
sone (153), pregabalin (25), sertraline (67), tramadol
(213), varenicline (29), venlafaxine (23), warfarin (16),
and zolpidem (554).
The performance analysis of the symptom dictionary-
matching algorithm based on a random sample of 10 % of
AE posts found precision was 72 % (410/573), and recall
was 86 % (410/475). The performance of the classiﬁer
validates the dictionary-matching approach itself, and also
indicates that the symptom counts used in the comparison
are close to what would have been derived by a purely
manual process.
The ﬁve pain reliever drugs we analyzed represent
multiple functional classes of compounds, over-the-counter
(OTC) versus prescription status, and new versus old drugs:
tramadol, oxycodone, naproxen, ibuprofen, and acetami-
nophen. Collectively, the medicines in this broad thera-
peutic area represent the most commonly mentioned
regulated drugs in our Twitter dataset.
3.1 Consumer-Reported AEs in the FDA AE Reporting
System (FAERS)
Exactly 1,400 events were reported by consumers to the
FDA during the two quarters for the products of interest,
corresponding to1,478uniquedrug–event pairs.For59.4 %
of events, the drugs were primary suspect agents; 33.1 %
were concomitant, and 7.5 % secondary suspect agents.
3.2 Overall Association between Twitter Posts
and FAERS
The preliminary analyses suggested that, when analyzed at
preferred-term levels, the sample was too noisy to provide
meaningful comparisons with FAERS due to the difference
in speciﬁcity between Internet vernacular on Twitter and
the depth of clinical distinctions in MedDRA. The overall
distribution proﬁles for AEs reported in Twitter and FA-
ERS for drugs were similar when analyzed by SOC
(Fig. 2). The Spearman correlation coefﬁcient was 0.75,
p\0.0001 (Fig. 3).
3.3 Vaccine AEs in Twitter and FAERS
We analyzed data for four common types of vaccines:
inﬂuenza, HPV, Tdap, and hepatitis B. Posts with AEs
mentioned in Twitter (posts 460, AEs 634, some posts
contained multiple AEs) were similar across vaccines.
Most vaccine AEs were associated with inﬂuenza vaccines
(posts 398, AEs 557), in part because ‘ﬂu shot’ was a
search term, whereas other vaccines did not have a corre-
sponding vernacular. The imbalance may also be due to the
differences in Twitter use among the populations receiving
Fig. 2 Correlation by system organ class between Proto-AEs in
Twitter and consumer reports in Food and Drug Administration
Adverse Event Reporting System (note log-log scale). AE adverse
event, FDA US Food and Drug Administration, Proto-AEs posts with
resemblance to adverse events
Digital Drug Safety Surveillance 347this vaccine versus others, given that it is an annual vaccine
indicated for nearly all individuals aged over 6 months.
Other vaccines had many fewer events, as shown in
Table 1. The most common AE by preferred term was
injection site pain, followed by pain, urticaria, and malaise.
4 Discussion
The recently passed FDA Safety and Innovation Act
(FDASIA) legislation (2012) and the FDA-issued report
Advancing Regulatory Science at FDA: A Strategic Plan
(2011) have emphasized the importance of post-market
safety surveillance and called for identiﬁcation of new
sources of post-market safety data. Accordingly, this ana-
lysis was intended to evaluate the potential value of bur-
geoning user-generated social media data in post-market
safety surveillance of drugs and biologics.
There were nearly three times as many Proto-AEs found
in Twitter data than reported to FDA by consumers, with
rank correlation between them at the SOC level. Further,
there was evidence that patients intend to passively report
AEs in social media, as evidenced by hashtags and men-
tions such as #accutaneprobz and @EssureProblems. Even
within 140 characters, some tweets demonstrate an
understanding of basic concepts of causation in drug safety,
such as alleviation of the AE after discontinuation of the
drug: ‘‘I found that Savella made my blood sugar [sic] high,
once I got off, my blood sugar returned to normal.’’
One of the key aspects of this research was to develop an
ontology that allowed translation between social media
vernacular and MedDRA, yielding strong automated clas-
siﬁcation performance as noted above. As an illustrative
example of this cross-ontology translation process, we
consider the tweet ‘‘Humira never really worked for me.
Orencia was good. Xeljanz was the best but ate a hole in my
Table 1 Proto-AEs collected from Twitter data on inﬂuenza vaccine, HPV vaccine, Tdap vaccine, and Hepatitis B vaccine
Vaccine Inﬂuenza HPV Tdap Hepatitis B
Unique posts 398 30 10 4
Vaccine-event
pairs
557 31 23 1
Key AEs Injection site pain; pain; malaise; purpura;
urticaria
Pain; injection site pain;
urticaria
Injection site pain; pain;
malaise
Pain;
fatigue
Proto-AE post with resemblance to adverse event, HPV human papillomavirus, Tdap tetanus/diphtheria/pertussis
Fig. 3 Rank order correlation by system organ class between Proto-AEs in Twitter and consumer reports in Food and Drug Administration
Adverse Event Reporting System (note log-log scale). AE adverse event, FDA US Food and Drug Administration, Proto-AEs posts with
resemblance to adverse events
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arthritis medicines, the ﬁrst product could be reported as
ineffective, but there is also a more serious event. The last
product mentioned what could be an exaggeration: ‘‘ate a
holeinmystomach.’’However,themedicationguideforthis
product states ‘‘XELJANZ may cause serious side effects
including: tears (perforation) in the stomach or intestines.’’
[17] The example illustrates that context is required to
interpret the ﬁndings, a task that humans inherently perform
betterthanmachines.Initially,identifyingthata‘‘holeinthe
stomach’’ could be a serious event required previous
knowledge of the labeled side effects [18]. We would likely
have been less concerned if the post seemed to be com-
plaining about routine gastrointestinal (GI) discomfort after
taking aspirin. As such, we believe that this is a task for
which humans are, for the time being, best suited. Advanced
methods to apply label information may alleviate this par-
ticular issue, but we found that a human curation step, after
the machine classiﬁed the posts, was the most efﬁcient way
to understand the nature of the problems reported.
Another illustrative example is paresthesia, often refer-
red to as ‘brain zaps’ or ‘head zaps’. These events have
been reported for rapid discontinuation of serotonergic
antidepressants as a class [19]. We found ample evidence
of the relatively new medicine vilazodone (marketed as
Viibryd) from patients: ‘‘Second day off Effexor & on
Viibryd here. Brain zaps are fun. And by fun, I mean
horrendous and miserable.’’ Also: ‘‘Viibryd side effects—
I’m having the awful head zaps too. They are mostly @
night when I’m laying down … .’’ The US prescribing
information in the label states that ‘‘paresthesia, such as
electric shock sensations’’ have been reported for the class
of antidepressants, but during clinical trials only two
patients in the treatment arm and one patient on placebo
experienced these sensations [20]. While this association is
not particularly unexpected, it demonstrates again how
knowledge of the label can help put ﬁndings from the
Internet in context and begins to suggest the rapidity with
which information can begin to ﬂow back to the public
authorities and manufacturers if social media data are
cleaned and curated in a thoughtful manner.
In addition to patients, clinicians may use Twitter to
communicate about cases that may involve AEs. For
example, the following post was made from the account of
an internal medicine resident at a hospital in the USA:
‘‘PMHx includes DVT x2 on xaerlto [sic], recurrent ton-
sillitis, former smoker, denies EtOH, denies surgeries, is
married.’’ The drug Xarelto (rivaroxaban) is indicated for
deep vein thrombosis, but it is unclear if the recurrent
tonsillitis is associated with the medicine. The US labeling
suggests increased incidence of sinusitis in one clinical trial
relative to placebo [21], and a post hoc analysis of a phase
III randomized trial found increased incidence of
respiratory tract or lung infections among participants with
higher body mass index (BMI) relative to comparator
(enoxaparin) [22]. Without emphasizing the particular
drug–event pair, we provide this example to show how
information from label studies, peer-reviewed research,
and regulatory databases can be used in conjunction with
social media to generate hypotheses for further testing.
While it may be feasible to review all social media posts
with Proto-AEs for lower volume drugs, there is likely to
be a point at which the volume of posts, say for a widely
used and established medicine, may overwhelm the
capacity for human review, requiring further automated
analysis. We also stress that, at this time, we do not rec-
ommend the wholesale import of individual social media
posts into post-marketing safety databases. Rather, in par-
allel with other post-marketing sources, these data should
be considered for idea generation, and reasonable hypoth-
eses followed up with formal epidemiologic studies.
Not all patients reporting side effects on Twitter are
capable of identifying them correctly, as seen in this
example: ‘‘I got the ﬂu shot yet somehow I’ve gotten the
stomach ﬂu twice in this month’’ where the vernacular
‘‘stomach ﬂu’’ would need to be translated into a medical
term, and the report was excluded from analysis because
the reported ineffectiveness does not correspond to an
indication or common off-label use for the vaccine. Other
errors may be inadvertent, but also need to be reviewed by
curators: ‘‘The act of kissing releases OxyContin in the
brain—a hormone that strengthens the emotional bond
between two people.’’ In this case, the likely intended
reference was to oxytocin, but this post is not characterized
as a Proto-AE because it did not include an adverse
reaction.
While providing initial qualitative information on the
identiﬁcation of Proto-AEs in Twitter data, this study has
limitations. First, the sample of posts involved was a
convenience sample enriched for positive AEs. These data
were assembled to deﬁne the Bayesian priors for an auto-
mated classiﬁcation system, and cannot be considered to be
representative of Twitter. We also did not fully de-dupli-
cate the posts at this point; for the moment, we assume that,
broadly aggregated, relative counts are stable even with
some duplication.
Additional work will include the development of
denominator-based pharmacoepidemiological methods to
establish baseline and threshold levels of signal for each
medical product such that when social media signals
deviate from these ‘norms’, users can be passively notiﬁed
of potential new safety signals. For now, this platform is
viewed as a hypothesis-generating system where potential
signal would be validated against more formal methods,
but it could potentially become a more conﬁrmatory
resource as our methods and validation are reﬁned.
Digital Drug Safety Surveillance 349Another key future direction for the work is in improved
usage of the existing FAERS and other ofﬁcial FDA data
sources. As mentioned above, currently FDA AE data are
often delayed and difﬁcult to use without extensive de-
duplication and other pre-processing steps. OpenFDA
(open.fda.gov) is a new initiative in the FDA Ofﬁce of
Informatics and Technology Innovation to offer open
access data and highlight projects in both the public and
private sector that use these data to further scientiﬁc
research, educate the public, and improve health. It is
expected to launch in fall 2014 and will provide API and
raw download access to a number of high-value structured
datasets, including open access AEs.
5 Conclusion
Proto-AEs identiﬁed in Twitter appear to have a similar
proﬁle by SOC to spontaneous reports received by the
FDA. Some high-volume products had hashtags for
reporting AEs (#accutaneprobz). Sample size for classiﬁed
reports needs to be increased before causal associations can
be made or signal identiﬁed for further investigation.
Future directions for research include assessing severity of
events, differentiating unlabeled events, time series mod-
eling, incorporation of patient and health Web sites, and
potentially search history data.
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